Ninerafaxstat improves symptoms, quality of life in nonobstructive HCM
ATLANTA â For patients with nonobstructive hypertrophic cardiomyopathy, ninerafaxstat, a novel cardiac mitotrope, safely improved HF symptoms during a 12-week period vs. placebo, a speaker reported.The results of the small phase 2 randomized controlled IMPROVE-HCM trial were presented at the American College of Cardiology Scientific Session and simultaneously published in the Journal of the